Each patient and their journey is unique – like a fingerprint. This requires individual therapies and patient approaches. But each patient’s story also has the unique potential to teach us something new about their disease and helps us discover more effective treatments.
At Temedica, we believe that individual treatment is the fundamental right of every patient. It is the key to improved quality of patient care. What stands in the way is the way in which today's approach to medical care is generally based on a "one size fits all" principle, ignoring the many different and unique patient journeys and experiences. This is a challenge that we aim to solve.
Innovative, digital solutions that put the patient back at the center
For personalized patient support, we develop digital companions that are indication-specific and tailored to the individual needs of each patient. Our digital companions cover a wide variety of use cases: starting in the context of clinical studies, through therapy support, to stand-alone digital therapeutics. They comply with all international standards (esp. MDR, FDA and ISO 13485) in terms of quality management and regulatory requirements.
Digital Patient Companions
Our Digital Patient Companions support faster and more accurate diagnosis and navigate patients through the healthcare system, acknowledging the unique and individual needs of each user. They encourage users to take their health actively into their own hands and promote compliance. Our Patient Companions are in continuous contact with their patients, enabling a deep understanding of their disease progression and the individual effectiveness of their therapy. Interfaces with treating Health Care Professionals (HCPs) provide them with longitudinal, real world insights into the individual patient’s condition and course of healing.
Digital Therapeutics (DTx)
Our end-to-end solution includes the development, launch and continuous operation of scalable Digital Therapeutics. They meet all quality management and regulatory requirements (MDR, FDA, etc.) and are therefore ideally suited for international deployment. Our Digital Therapeutics are DVG compliant and as a result meet the German reimbursement basis for Digital Health Applications (German: DiGAs). In terms of reimbursability of Digital Therapeutics, we have many years of experience and cooperate with a large number of health insurance companies.
Digital Trial Companions
Our Digital Trial Companions support modern data collection in the context of clinical studies. They provide longitudinal patient-reported outcomes of different types with high temporal resolution. Using our study-specific “companion in the patient’s pocket” and its easy-to-use and motivating user interface, we improve overall study compliance and adherence.
Temedica’s App Platform
Our app platform technology has an excellent track record across many different application areas with our pharma and medtech partners, delivering measurable results thanks to consistent quality management and compliance with all regulatory requirements. Efficiency-enhancing synergies are created not only across products, but also in terms of time-to-market and commercialization. Our platform is the basis for agile and replicable development of new digital companions, which of course meet all MDR and FDA requirements.
Thanks to our app platform technology, our partners from pharma, biotech and medtech spaces - alongside those from academia - can fully focus on their core diagnostic and therapeutic competencies and benefit from our modular and freely configurable platform elements. As a result, our app platform allows significantly faster commercialization and global scalability of digital solutions.
Covering development, go-to-market and operations of digital health solutions
Supporting compliance and improving health outcomes
Direct patient access
Thanks to a holistic offering throughout the entire patient journey
Quality management as per ISO 13485
FDA & MDR
Fulfillment of all regulatory requirements for FDA & MDR
Many years of experience
Concerning the reimbursability of digital health solutions
Hundreds of thousands of patients use our digital patient companions
Temedica offers patient-centric digital companions in the form of apps for an ever-growing number of indicators. These mobile apps accompany patients on their health journey and support them with personalized and therapy-supporting guidance.
Thanks to Temedica, we have found a regulatory compliant way to close the gap to our patients. The collaboration over several years has not only resulted in a great digital patient solution for us, but also in many valuable insights about digitization in the industry!
pelvina is a digital course to strengthen the female pelvic floor and to reduce urinary incontinence. The effectiveness of pelvina has been proven in clinical studies. With several hundred thousand users, pelvina is the market leader in Europe.
Mineo provides an online platform where doctors and therapists can create individual therapy plans for back pain patients and monitor the progress of their personal recoveries.
With Temedica, we have a competent and professional partner who will work together with us to further develop and drive forward the topic of digital patient support with the aim of achieving sustainable behavioral change. Temedica's digital competence, speed and creative start-up mentality are a valuable addition to our long-standing expertise and presence in the market.
Our collaboration with Temedica is creative, motivating, professional and at eye level. At Temedica, the users are in the focus and they are involved individually.
Waya helps overweight people to reduce their weight sustainably. They learn how to integrate healthy nutrition and physical exercise programs into their everyday lives.
With Temedica, we have a dynamic, agile and inspirational partner, who helps us to move forward faster in our digital transformation and to unlock the potential of the digital world.
The success of our clinical studies rises and falls with the motivation of the participants to continuously and reliably transmit their measured data. Here, we recorded significant and, above all, stable improvements compared to our previous studies shortly after we started using Temedica's digital trial companions.